Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DBM-1152A Inhalation Solution in Healthy Chinese Subjects
NCT07447141Phase 1Completed
- Sponsor
- Joincare Pharmaceutical
- Start
- Dec 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DBM-1152A in asthma and chronic obstructive pulmonary disease (COPD), sponsored by Joincare Pharmaceutical. Primary endpoints: Treatment-Emergent Adverse Events at Day 4 and Serious Adverse Events at Day 4. Started Dec 2023; status: completed.
02
Drugs
DBM-1152A
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07447141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07447141.